Horizon Therapeutics Plc HZNP Stock Price Today, Quote, Latest Discussions, Interactive Chart and News

Amgen late last year agreed to acquire Horizon in a deal valued at nearly $28 billion. Shares of Horizon Therapeutics rose Friday morning after the FTC said it reached a settlement with Amgen that would let it acquire the company.

• The stock is down more than 28% this year and trading at just under 7 times earnings.
• Organon, like Viatris, is a spinoff that hasn’t exactly caught on with investors yet, despite its financial strength.
• A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares.
• The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019.

The biopharmaceutical company released its latest quarterly update. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Organon, like Viatris, is a spinoff that hasn’t exactly caught on with investors yet, despite its financial strength.

Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others. 8 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Horizon Therapeutics Public in the last twelve months. The consensus among Wall Street research analysts is that investors should “hold” HZNP shares.

Horizon Therapeutics (HZNP) Up 10.4% Since Last Earnings Report: Can It Continue?

Hadlima, priced at 85% less than Humira, is expected to have strong sales. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.

As of August 31st, there was short interest totaling 9,480,000 shares, an increase of 20.6% from the August 15th total of 7,860,000 shares. Based on an average daily trading volume, of 2,300,000 shares, the short-interest ratio is currently 4.1 days. One driver of the company’s growth was its portfolio of women’s health products, sales of which were up 8% year over year, led by a 12% sales gain by reversible contraceptive Nexplanon. Additionally, sales of Organon’s biosimilars were up 14% over the same period last year. The biosimilar sales surge was led by Renflexix, a biosimilar to Remicade, which is used to treat autoimmune disorders and sold by Johnson & Johnson subsidiary Janssen.

Click the link below and we’ll send you MarketBeat’s guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Horizon Therapeutics’s shares are up almost 200% over the past 12 months, buoyed by mind-boggling sales of its new blockbuster drug. Volatility profiles what do you mean by transfer based on trailing-three-year calculations of the standard deviation of service investment returns. Management now expects yearly revenue to be between $6.25 billion and $6.45 billion, compared to $6.2 billion last year. Most of the company’s pipeline, though, is made of early-stage candidates.

NEWS: Horizon to be acquired by Amgen. For important information, read more.

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company’s employees. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Horizon Therapeutics has a clear path to significant sales growth. Horizon’s shares were recently up more than 2%, while Amgen’s ticked higher.

The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI,… The company recently raised its quarterly dividend by 5% to $0.36, which at the current share price gives it a yield of just under 4%. During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Shares of GSK (formerly GlaxoSmithKline) are down by more than 2% so far this year, and the stock is trading at a price-to-earnings ratio of slightly above 4.

Stock Money Flow

Viatris, which was formed in 2020 via the merger of Mylan and the Upjohn division of Pfizer, is down by more than 8% so far this year. The company’s revenue, built on legacy branded drugs and generics, has been slipping, but Viatris remains profitable and has several new biosimilar products that (in time) are expected to reverse that revenue slide. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.

On average, healthcare stocks haven’t kept up with the gains made by the rest of the market this year. While the S&P 500 index is up by more than 17% year to date, that sector’s stocks are down by nearly 3%. That trend, though, created some great opportunities to get in on solid value stocks that are underpriced and offer solid dividends. Horizon Therapeutics Public saw a increase in short interest in August.

The company boosted its quarterly payout by 9% last year to $0.12 per share. The stock is down more than 28% this year and trading at just under 7 times earnings. In the second quarter, Organon reported revenue of $1.61 billion, up 1% year over year and 4% sequentially.

Horizon Therapeutics PLC (HZNP)

To see all exchange delays and terms of use please see Barchart’s disclaimer. The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. On Tuesday, the company received tentative approval from the FDA for its abacavir/dolutegravir/lamivudine triple therapy, its biosimilar which will be used as a treatment for pediatric patients with HIV-1. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements.

Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases.

However, that also means it has the potential for solid long-term growth. The company is seeing strong growth from its recently approved shingles vaccine, Shingrix, as well as from the new respiratory syncytial virus vaccine Arexvy. It also just got FDA approval on July 31 for Jemperli to be used as a front-line combination therapy with chemotherapy to treat endometrial cancer. The company is awaiting the FDA’s decision on its myelofibrosis therapy candidate momelotinib. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.

Earnings for the quarter were $0.22 per share, down from $0.26 per share in Q2 2022, but up from $0.19 per share in Q1 2023. Organon also has the best dividend yield of these three companies at around 5.6%, thanks to a quarterly dividend of $0.28 per share, though its payout has held steady at that level for several years. In the second quarter, the company reported revenue of $8.9 billion, up 4%, year over year, but if COVID-19 sales were taken out of the picture, revenue would have been up 11%. GSK also reported net income of $2 billion, up 98%, year over year. Viatris (VTRS 0.82%), GSK (GSK 1.71%), and Organon (OGN 2.70%) are too inexpensive to pass up at this point. All three pharmaceutical stocks trade at under 7 times earnings and have forward price-to-earnings ratios of less than 10.

This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply. We’d like to share more about how we work and what drives our day-to-day business. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. See
HZNP’s valuation ratios
compared to the Market Index. Upgrade to MarketBeat All Access to add more stocks to your watchlist.

How has HZNP performed historically compared to the market?

It also reported net income of $242 million, up 3% year over year and 36.7% sequentially. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

That’s incredibly low considering that the company is growing revenue even as its COVID-19-related sales erode. Viatris reported second-quarter revenue of $3.91 billion, down 5% year over year, but up 5% sequentially. That total included $124 million in new product revenue, and the company said it is on track for $500 million in new product revenue this year.

A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares. Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. Viatris investors can afford to be patient as they wait for growth to return thanks to a generous dividend that at the current share price yields around 4.7%.

• Earnings for the quarter were $0.22 per share, down from $0.26 per share in Q2 2022, but up from $0.19 per share in Q1 2023.
• As of August 31st, there was short interest totaling 9,480,000 shares, an increase of 20.6% from the August 15th total of 7,860,000 shares.
• Hadlima, priced at 85% less than Humira, is expected to have strong sales.
• The company’s revenue, built on legacy branded drugs and generics, has been slipping, but Viatris remains profitable and has several new biosimilar products that (in time) are expected to reverse that revenue slide.
• Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

Let’s look at some other reasons these three pharmaceutical stocks are too cheap to ignore. HZNP’s beta can be found in Trading Information at the top of this page. A stock’s beta https://1investing.in/ measures how closely tied its price movements have been to the performance of the overall market. One share of HZNP stock can currently be purchased for approximately $115.35.